Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9125 USD | -1.13% | -4.25% | -33.88% |
Mar. 27 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Mar. 27 | Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.88% | 178M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- bluebird bio : EMA Panel Issues Positive Opinion on bluebird bio's Gene Therapy for Metabolic Disorder